Gerda M Saletu-Zyhlarz Selected Research

ABIO 0801

1/2009

Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 1. EEG mapping, psychometric and tolerability findings.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gerda M Saletu-Zyhlarz Research Topics

Disease

2	Restless Legs Syndrome (Restless Legs) 01/2016 - 04/2007
2	Anxiety Disorders (Anxiety Disorder) 01/2009 - 06/2000
2	Mental Disorders (Mental Disorder) 04/2006 - 04/2005
1	Narcolepsy 02/2005
1	Sleepiness 02/2005
1	Panic Disorder (Panic Attack) 06/2000
1	Sleep Initiation and Maintenance Disorders (Insomnia) 06/2000

Drug/Important Bio-Agent (IBA)

3	Pharmaceutical PreparationsIBA 04/2006 - 06/2000
2	Psychotropic Drugs (Psychoactive Drugs)IBA 04/2006 - 04/2005
1	Oxycodone (Oxycontin)FDA LinkGeneric 01/2016
1	Naloxone (Narcan)FDA LinkGeneric 01/2016
1	ABIO 0801IBA 01/2009
1	levodopa drug combination benserazideIBA 04/2007
1	Cabergoline FDA LinkGeneric 04/2007
1	Levodopa (L Dopa)FDA LinkGeneric 04/2007
1	Dopamine Agonists (Dopamine Agonist)IBA 04/2007
1	Modafinil (Provigil)FDA Link 02/2005
1	BenzodiazepinesIBA 06/2000
1	Alprazolam (Xanax)FDA LinkGeneric 06/2000

Therapy/Procedure

3	Therapeutics 04/2007 - 06/2000